Clinical trial
A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB)
NCT03086486 is registered in ClinicalTrials.gov with Global Alliance for TB Drug Development as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB)
- Lead sponsor
- Global Alliance for TB Drug Development
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 21, 2017
- Completion date
- February 8, 2022
- Enrollment
- 181 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
extensively drug-resistant tuberculosis, pre-xdr-tb, tuberculosis, tuberculosis, mdr, tuberculosis, multidrug-resistant, tuberculosis, pulmonary, xdr-tb